Dr. Parameswaran Hari discusses the importance of understanding a patient’s MRD if they are receiving the maintenance therapy Sarclisa for multiple myeloma.
Dr. Parameswaran Hari
Advertisement
Articles by Dr. Parameswaran Hari
Advertisement
Latest Updated Articles
Minimal Residual Disease is A Vital Marker for Patients with Multiple Myeloma, Says ExpertPublished: July 31st 2020 | Updated:
Advertisement
Advertisement
Trending on CURE
1
FDA Grants Exousia Pro Orphan Drug Designation in Glioma
2
With Cancer, 'Your Outlook Will be Significant in Beating this Disease'
3
What to Know About the FDA Approval of Blenrep for Multiple Myeloma
4
Advancing Research Offers Hope for Patients With Liver Cancer
5
